Herbal granules may knock out cold symptoms in three days — a rigorous trial puts them to the test

NCT ID NCT07720583

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This phase 3 trial tests whether Jinhua Qinggan Granules, a traditional Chinese herbal medicine, can eliminate symptoms of acute upper respiratory infections (like fever, sore throat, and congestion) within three days. About 273 adults with early-stage cold or flu will receive either the herbal granules or a placebo three times daily. The goal is to see if the treatment can bring total symptom scores to zero and keep them there for at least 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Jinhua Qinggan Granules, a traditional Chinese medicine herbal formula
What this could lead to
If effective, this herbal treatment could offer a new option for speeding recovery from common cold-like infections.
What could go wrong
This is a single trial with 273 participants, and herbal remedies often show mixed results. The placebo effect may be strong for symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

546 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed with AURI; 2. Wind-heat of TCM pattern differentiation; 3. 18 ≤Age ≤ 65; 4. At screening, axillary temperature ≥37.3 ºC and ≤39.0 ºC; 5. At randomization and group assignment, disease course within 48 hours; 6. The subject has signed the informed consent form. Exclusion Criteria: 1. Patients with influenza, COVID-19, suppurative otitis media, suppurative tonsillitis, acute attack of asthma and chronic obstructive pulmonary disease, pulmonary tuberculosis, primary ciliary dyskinesia syndrome, pleural effusion, interstitial lesions, acute and chronic tracheobronchitis, lower respiratory infections such as pneumonia; 2. WBC \> 11.0×109 or NEU% \> 80% or with symptoms of thick sputum and suspected bacterial infection; 3. ALT, AST \> 2 ULN or CRE\>ULN; 4. Nasal surgery, nasopharyngeal radiotherapy, acute and chronic nasal diseases or abnormal nasal mucosal function (e.g. rhinitis, sinusitis); 5. Patients with diseases diagnosed by specific pathogens (e.g. mumps, measles, hemorrhagic fever, typhoid, chicken pox, allergic rhinitis); 6. Fever caused by other clearly diagnosed organic diseases outside the respiratory system; 7. Accompanied by cardiovascular diseases (e.g. coronary heart disease, myocarditis, etc., excluding hypertension with stable blood pressure control and asymptomatic old lacunar infarction), major kidney, liver, hematological diseases, major nervous and neuromuscular diseases, major metabolic and endocrine diseases and immunosuppression (including immunosuppressant or HIV infection, etc.), and malignant tumor; 8. Subjects, who were treated with antivirals, antibiotics, western or traditional medicines for alleviating symptoms of upper respiratory infection within 12 hours before enrollment; 9. Allergic individuals and those who are known to be allergic to investigational drugs, including the ingredients of this product, acetaminophen or drug excipients; 10. Women who are pregnant or plan to become pregnant within the next 1 months, lactating women; from signature of informed consent form, until 30 days after the last study medication, patients of childbearing age who are unable or unwilling to use adequate contraception or their spouses are unwilling to use contraception; 11. Suspected or do have a history of alcohol or drug abuse; 12. Participated in other clinical trials or are participating in other clinical trials in the past 3 months; 13. Subjects not suitable for enrollment based on investigators' judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pharyngitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi

    Karachi, Karachi, 75270, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.